Company Overview of Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. develops therapies for the treatment of dyslipidemia and cardiovascular diseases. Its products include Epanova, an Omega 3 fatty acid that has completed Phase III clinical studies to treat patients with triglycerides. The company has a license agreement with Chrysalis Pharma AG to develop and commercialize Epanova; and an agreement with BioVectra Inc. for the manufacture of the active pharmaceutical ingredient for Epanova. Omthera Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Princeton, New Jersey. Omthera Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
707 State Road
Princeton, NJ 08540
Founded in 2008
Key Executives for Omthera Pharmaceuticals, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Omthera Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.